Introduction

ReLIA Biotechnologies (Jiangsu), Inc. is a wholly-owned subsidiary of ReLIA Diagnostic Systems, USA. The company was founded in China Medical City (CMC), Taizhou, China in 2010, with registered capital of 2.3 million USD and total investment of 4.6 million USD.

ReLIA Diagnostic Systems has developed a low-cost, high-performance portable immunoassay system for point-of-care (POC) diagnosis that provides high sensitivity, precision, accuracy and reliability of expensive and complex central laboratory systems, with the advantage of bedside testing.

Its state-of-art manufacturing facility has received GMP certification from Chinese SFDA for manufacturing medical device and diagnostic reagent products. It also provides market with products that CE-marked.


一、公司簡(jiǎn)介
瑞萊生物科技（江蘇）有限公司是美國(guó)著名的ReLIA生物醫(yī)療診斷公司在中國(guó)的獨(dú)資企業(yè)，于2010年在江蘇泰州中國(guó)醫(yī)藥城成立，注冊(cè)資金230萬(wàn)美元，投資總額超過(guò)460萬(wàn)美元。
瑞萊公司主要從事體外診斷試劑，特別是即時(shí)檢驗(yàn)技術(shù)（POCT）產(chǎn)品的研發(fā)、生產(chǎn)及銷(xiāo)售，研制開(kāi)發(fā)出具有國(guó)際自主知識(shí)產(chǎn)權(quán)的ReLIA 多功能免疫檢測(cè)系統(tǒng)?，F(xiàn)公司已經(jīng)獲得：國(guó)家食品藥品監(jiān)督管理局(SFDA)頒發(fā)的《醫(yī)療器械生產(chǎn)許可證》、歐盟的CE認(rèn)證，公司最終將通過(guò)美國(guó)的FDA認(rèn)證。
ReLIA 多功能免疫檢測(cè)系統(tǒng)具備了“快速、定量、全血檢測(cè)、使用簡(jiǎn)便”等即時(shí)檢驗(yàn)技術(shù)的必備條件，是國(guó)內(nèi)率先擁有國(guó)際自主知識(shí)產(chǎn)權(quán)的POCT技術(shù)產(chǎn)品。